CAR-T Cell Therapy Combined with PD-1 Inhibitors in Cancer: Synergistic Antitumor Mechanisms, Clinical Progress, and Future Perspective
Among the most transformative advances in cancer immunotherapy, chimeric antigen receptor (CAR)-T cell therapy and inhibitors of programmed cell death protein 1 (PD-1) stand out, yet each approach carries its own weaknesses. CAR-T therapy produces dramatic responses in hematologic malignancies, although T-cell exhausti...